117 related articles for article (PubMed ID: 36840671)
1. Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors.
Dmochowska N; Milanova V; Mukkamala R; Chow KK; Pham NTH; Srinivasarao M; Ebert LM; Stait-Gardner T; Le H; Shetty A; Nelson M; Low PS; Thierry B
Small; 2023 May; 19(21):e2204956. PubMed ID: 36840671
[TBL] [Abstract][Full Text] [Related]
2. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer.
Tse BW; Cowin GJ; Soekmadji C; Jovanovic L; Vasireddy RS; Ling MT; Khatri A; Liu T; Thierry B; Russell PJ
Nanomedicine (Lond); 2015 Feb; 10(3):375-86. PubMed ID: 25407827
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
Ngen EJ; Chen Y; Azad BB; Boinapally S; Jacob D; Lisok A; Shen C; Hossain MS; Jin J; Bhujwalla ZM; Pomper MG; Banerjee SR
Nanotheranostics; 2021; 5(2):182-196. PubMed ID: 33564617
[TBL] [Abstract][Full Text] [Related]
4. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy.
Ngen EJ; Benham Azad B; Boinapally S; Lisok A; Brummet M; Jacob D; Pomper MG; Banerjee SR
Mol Pharm; 2019 May; 16(5):2060-2068. PubMed ID: 30912947
[TBL] [Abstract][Full Text] [Related]
5. Quantitative [Fe]MRI determination of the dynamics of PSMA-targeted SPIONs discriminates among prostate tumor xenografts based on their PSMA expression.
Sillerud LO
J Magn Reson Imaging; 2018 Aug; 48(2):469-481. PubMed ID: 29331081
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging.
Kessel K; Seifert R; Weckesser M; Boegemann M; Huss S; Kratochwil C; Haberkorn U; Giesel F; Rahbar K
Ann Nucl Med; 2022 Mar; 36(3):293-301. PubMed ID: 34854061
[TBL] [Abstract][Full Text] [Related]
7. Hetero-bivalent agents targeting FAP and PSMA.
Boinapally S; Lisok A; Lofland G; Minn I; Yan Y; Jiang Z; Shin MJ; Merino VF; Zheng L; Brayton C; Pomper MG; Banerjee SR
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4369-4381. PubMed ID: 35965291
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Preclinical Evaluation of Three Novel
Verena A; Zhang Z; Kuo HT; Merkens H; Zeisler J; Wilson R; Bendre S; Wong AAWL; Bénard F; Lin KS
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770755
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging.
Wang P; Wang S; Liu F; Ren Y; Guo Q; Zhang Q; Hou X; Yao Y; Zhu H; Yang Z
Mol Pharm; 2023 Feb; 20(2):1415-1425. PubMed ID: 36697367
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of Gd-Based prostate cancer targeted magnetic resonance agents using prostate specific membrane antigen.
Yang JU; Kim S; Ahn JH; Kim MH; Kil HS; Chi DY; Lee KC; Lee YJ; Park JA
Biochem Biophys Res Commun; 2022 Jun; 607():152-157. PubMed ID: 35367828
[TBL] [Abstract][Full Text] [Related]
12. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
Zamboglou C; Wieser G; Hennies S; Rempel I; Kirste S; Soschynski M; Rischke HC; Fechter T; Jilg CA; Langer M; Meyer PT; Bock M; Grosu AL
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):889-897. PubMed ID: 26592938
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles.
Zhu Y; Sun Y; Chen Y; Liu W; Jiang J; Guan W; Zhang Z; Duan Y
Int J Mol Sci; 2015 Apr; 16(5):9573-87. PubMed ID: 25927579
[TBL] [Abstract][Full Text] [Related]
14. Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels.
Sillerud LO
Int J Nanomedicine; 2016; 11():357-71. PubMed ID: 26855574
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI.
Pu F; Salarian M; Xue S; Qiao J; Feng J; Tan S; Patel A; Li X; Mamouni K; Hekmatyar K; Zou J; Wu D; Yang JJ
Nanoscale; 2016 Jul; 8(25):12668-82. PubMed ID: 26961235
[TBL] [Abstract][Full Text] [Related]
16. Focal dose escalation for prostate cancer using
Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
[TBL] [Abstract][Full Text] [Related]
17. Construction and in vitro/in vivo targeting of PSMA-targeted nanoscale microbubbles in prostate cancer.
Wang L; Li L; Guo Y; Tong H; Fan X; Ding J; Huang H
Prostate; 2013 Aug; 73(11):1147-58. PubMed ID: 23532872
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner.
Taylor RM; Sillerud LO
Int J Nanomedicine; 2012; 7():4341-52. PubMed ID: 22915856
[TBL] [Abstract][Full Text] [Related]
19. Optimized Anti-Prostate-Specific Membrane Antigen Single-Chain Variable Fragment-Loaded Nanobubbles as a Novel Targeted Ultrasound Contrast Agent for the Diagnosis of Prostate Cancer.
Ding Y; Cao Q; Qian S; Chen X; Xu Y; Chen J; Shen H
J Ultrasound Med; 2020 Apr; 39(4):761-773. PubMed ID: 31702068
[TBL] [Abstract][Full Text] [Related]
20. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
